Chronic Kidney Disease (CKD) can cause growth problems in children. This condition
will affect children’s social life and increase morbidity and mortality. Growth
hormone (GH) is one of medication that has been used for treatment of impaired
growth in children with chronic kidney disease. In Indonesia, this management has
not been provided, because it is expensive and its effectiveness is uncertain. This
research was conducted to determine the effectiveness of growth hormone in
increasing linear growth in children with CKD. This study is a systematic review of
the Randomized Controlled Trial (RCT) study to determine the effectiveness of growth
hormone as a treatment for children with CKD. Literature search was conducted
using five databases, namely Pubmed, Google Scholar, DOAJ, BMC and CENTRAL
that matched the inclusion and exclusion criteria. The guide used in the literature
selection was the PRISMA flow chart. A Total of 10 studies were included in the
systematic review. Growth hormone is effective in increasing linear growth in
children with CKD. Generally there was a significant increase in height (standard
deviation (SD)), high velocity (SD or cm) in the therapy group compared to the control
group. The dose of growth hormone that is given varies, but the most is 4 IU / m2 /
day, once a day, by subcutaneous injection. The duration of growth hormone
administration varied from 6 months to 5 years with an average of 1.7 years. Growth
hormone did not aggravate kidney problems in children with CKD and can increase
important factors in bone formation, namely alkaline phosphatase and osteocalcin.